Parabilis Medicines

Parabilis Medicines is a clinical-stage biopharmaceutical company creating groundbreaking therapies by targeting previously undruggable biological pathways. They have developed Helicon™ peptides, a novel class of alpha-helical peptides, which are engineered to modulate intracellular proteins effectively. With a focus on diseases driven by the Wnt/β-catenin pathway, their lead candidate, zolucatetide, represents a unique solution for patients facing serious health challenges.